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Oligodendrocyte precursor cells (OPCs) constitute the main pro-
liferative cells in the adult brain, and deregulation of OPC
proliferation-differentiation balance results in either glioma forma-
tion or defective adaptive (re)myelination. OPC differentiation
requires significant genetic reprogramming, implicating chromatin
remodeling. Mounting evidence indicates that chromatin remod-
elers play important roles during normal development and their
mutations are associated with neurodevelopmental defects, with
CHD7 haploinsuficiency being the cause of CHARGE syndrome and
CHD8 being one of the strongest autism spectrum disorder (ASD)
high-risk–associated genes. Herein, we report on uncharacterized
functions of the chromatin remodelers Chd7 and Chd8 in OPCs.
Their OPC-chromatin binding profile, combined with transcriptome
and chromatin accessibility analyses of Chd7-deleted OPCs, demon-
strates that Chd7 protects nonproliferative OPCs from apoptosis by
chromatin closing and transcriptional repression of p53. Further-
more, Chd7 controls OPC differentiation through chromatin open-
ing and transcriptional activation of key regulators, including Sox10,
Nkx2.2, and Gpr17. However, Chd7 is dispensable for oligodendro-
cyte stage progression, consistent with Chd8 compensatory func-
tion, as suggested by their common chromatin-binding profiles
and genetic interaction. Finally, CHD7 and CHD8 bind in OPCs to a
majority of ASD risk-associated genes, suggesting an implication of
oligodendrocyte lineage cells in ASD neurological defects. Our re-
sults thus offer new avenues to understand andmodulate the CHD7
and CHD8 functions in normal development and disease.
oligodendrocyte | chromatin remodeling | CHARGE | autism spectrum
disorder | transcription regulation
Beyond the well-known function in saltatory conduction ofaction potentials, oligodendrocytes (OLs) have been shown
to metabolically support axons with lactate shuttling through the
myelin sheaths (1, 2). Accumulating evidence over the last years
has demonstrated a role for neuronal activity-dependent adap-
tive myelination in adult brain plasticity, which confers a key
neurological function to OL lineage cells (3). Oligodendrocyte
precursor cells (OPCs) originate from focal regions of ventricu-
lar zones in the brain and spinal cord (4, 5) and, through pro-
liferation and migration, occupy the whole CNS before starting
to differentiate into myelinating OLs (6). Unlike most precursor
cells, OPCs remain abundant in the adult CNS, being one of its
neural cell subtypes (7, 8). OPCs need to keep a tight balance
between proliferation, survival, and differentiation. This balance
is crucial to maintain the OPC pool while contributing to myelin
plasticity in adult life, and to remyelination in diseases, such as
multiple sclerosis (MS). A large diversity of extrinsic signals (9),
as well as many transcription factors [TFs, reviewed in Emery
and Lu (10)], have been involved in OPC proliferation, survival,
and differentiation. However, the mechanism for how these
signals are integrated in the nucleus to balance OPC behavior is
largely unknown.
OPC differentiation requires profound changes in chromatin
and gene expression (10, 11). TFs, such as Sox10, Olig2, Nkx2.2,
or Ascl1, are key regulators of OL differentiation by directly
controlling transcription of genes implicated in this process (12–
15) but being already expressed in OPCs, it is still unclear how
these TFs control the induction of differentiation. A growing
body of evidence suggests that some of these TFs work together
with chromatin ` factors during transcriptional initiation/elon-
gation to drive robust transcription (16). Accordingly, Olig2 and
Brg1, a SWI/SNF chromatin remodeler expressed in oligoden-
droglia, have been found to cooperate and promote the ex-
pression of OPC differentiation genes (15).
Chd7 and Chd8, ATP-dependent nucleosome remodeling
factors belonging to the subgroup III of the chromodomain
helicase DNA-binding (CHD) family modulate the chromatin
configuration to regulate the temporal and spatial expression of
genes during development (17, 18) and, more specifically, neu-
rogenesis (19–23). Importantly, while CHD7 mutations are the
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main cause of CHARGE syndrome, an autosomal-dominant
syndrome that often impairs normal brain development, leading
to cognitive disabilities (24), CHD8 is one of the nine high-
confidence autism spectrum disorder (ASD)-risk genes (25, 26)
and autism features are found in some CHARGE syndrome pa-
tients (27). We recently showed that Chd7 expression is highly
enriched in OL lineage cells and by Chd7 loss-of-function (LOF)
experiments demonstrated that Chd7 is required for myelination
and remyelination through cooperation with Sox10 and activation
of myelin-associated gene expression (28). In the present study, we
have investigated the role of Chd7 in OPC cell fates and explored
the possible redundancy with its paralog gene, Chd8. Indeed,
Chd8 is another CHD subgroup III protein previously shown to
interact with Chd7 (21, 29), and although Chd8 plays an important
role in neurodevelopment (22, 23), its function in glial cells has
not been investigated so far. Here, using a time-controlled Chd7
deletion in OPCs, we show that Chd7 inactivation leads to de-
creased OPC survival specifically in noncycling OPCs and that, in
parallel, OPC differentiation is reduced without affecting OL
stage progression due to Chd8 functional compensation. Com-
bining Chd7/Chd8 chromatin-binding profiles from in vivo OPCs
with transcriptome and chromatin accessibility analyses of Chd7-
deleted OPCs, we demonstrate that mechanistically, Chd7 pro-
motes OPC survival via chromatin closing and transcriptional re-
pression of p53/Trp53, while conversely, Chd7 binding is required
for chromatin opening and transcriptional activation of key reg-
ulators of OPC differentiation. Finally, integration of chromatin-
binding profiles and associated epigenetic signals from OL lineage
cells suggest that Chd7/Chd8 remodelers and Olig2/Sox10 TFs
cooperate to activate oligodendroglia stage-specific genes in a
time-controlled manner.
Results
Chd7 Binds to Promoters and Enhancers of Genes Involved in OPC
Differentiation, Proliferation, and Survival. Chd7 is known to be
required for the normal onset of myelination (28) but its in-
volvement in early stages of oligodendroglial cell lineage has not
been addressed. In support for Chd7’s role in OPC cell-fate de-
cisions, we found that Chd7 protein was expressed at the OPC
stage (Fig. 1 A–C, arrowheads, and SI Appendix, Fig. S1) and ac-
cumulated in immature OLs (iOLs) (Fig. 1 A–C, arrows, and SI
Appendix, Fig. S1) (28). OPCs show a tight balance between pro-
liferation and differentiation by mechanisms that are not com-
pletely understood. We therefore investigated the possible
regulation of Chd7 in OPC proliferation, survival, and differenti-
ation by generating a chromatin-binding profile of Chd7 in purified
OPCs. Using magnetic-assisted cell sorting (MACS) from mouse
postnatal day (P) 7 cortices (Fig. 1D), we prepared highly purified
O4+ oligodendroglia (98%, being ∼80% of PDGFRα+ OPCs and
∼20% of Nkx2.2+/CNP+ iOLs) (SI Appendix, Fig. S2 A–C), directly
used to perform Chd7 chromatin-binding analysis by ChIP com-
bined with high-throughput sequencing (ChIP-seq) (Fig. 1D), and
identified 11,655 Chd7-binding sites associated with 6,018 protein-
coding genes (Fig. 1 E and F). Remarkably, almost all (94%) of
Chd7-bound genes had a dynamic expression pattern in OL lineage
cells (SI Appendix, Fig. S2D). To investigate whether Chd7 binding
in OPCs was stage-specific, we compared Chd7-binding sites in
OPCs to our previous data from OLs (28). We found that Chd7
Fig. 1. Chd7 bind to genes involved in OPCs proliferation, differentiation, and survival. (A and B) Immunostaining of Chd7 with PDGFRα and CC1 (A) or
Olig1 and CC1 (B) in the CC of P24 mice. Gray arrowheads show OPCs and gray arrows show OLs. (Scale bar, 10 μm.) (C) Scheme representing expression levels of
different markers depending on OL stage. (D) Diagram representing MACSorting of O4+ cells of P7 wild-type mice followed by Chd7 ChIP-seq. (E and F) Venn
diagrams depicting the overlap of Chd7-binding sites (E) and bound genes (F) in OPCs and OLs, with examples of genes involved in OPC differentiation (blue),
cell death (orange), and cell cycle (red). (G) Barplot representing the GO analysis of the OPC- or OL-only Chd7-bound genes. (H) Representative ChIP-seq tracks for
Chd7 and control IgG together with active epigenetic marks (H3K27ac and H3K4me3) of Trp53, Ccnd1, and Sox10 genes in OPCs and OLs. (I and J) Graph showing
the number of correlations of Chd7 peaks in OPCs (blue) and OLs (black) compared with the position in enhancer regions (I) and promoter regions (J).
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binds only 10% of common sites at both stages (1,279) (Fig. 1E),
corresponding to ∼30% of commonly bound genes (2,168) (Fig. 1F).
These genes included key regulators of oligodendrogenesis (Ascl1,
Olig1, Sox10,Nkx2.2) (Fig. 1 F andH). Notably, gene ontology (GO)
enrichment analysis indicated that, in OPCs, Chd7 binds genes in-
volved in proliferation (such as Ccnd1, Cdk4, and Cdk6) and apo-
ptosis (such as p53/Trp53), while myelin-genes (such as Mobp and
Omg) were Chd7-bound only in OLs (Fig. 1 F–H). Therefore,
Chd7 binds in a stage-specific manner to genes implicated in oli-
godendroglial cell survival, proliferation, and differentiation.
We assessed the cell-type specificity of Chd7 chromatin binding
by comparing its binding profile in OPCs, embryonic stem cells
(ESCs) (30), OLs (28), and neonatal cerebellar granule precursors
(GNPs) (21). Interestingly, Chd7-binding profiles in ESCs, OPCs,
and OLs overlapped only in 151 peaks (representing 1% of OPC
peaks), with 14% of OPC peaks shared with ESCs (SI Appendix,
Fig. S2E). Similarly, only 63 peaks overlapped between OPCs,
OLs, and GNPs, with 4% of OPC peaks shared with GNPs (SI
Appendix, Fig. S2F). The Chd7 chromatin binding is thus mostly
cell-type– and lineage-stage–specific.
We next examined whether Chd7 preferentially binds enhancer
elements in OPCs, as has been reported in ESCs (17, 30). To
identify enhancer elements in OPCs, we took advantage of
oligodendroglia-specific ChIP-seq datasets for Sox10 and Olig2,
key TFs activating oligodendrogenesis (15, 28). In oligodendrog-
lial cells, Sox10/Olig2-commonly bound regions (12,094) (SI Ap-
pendix, Fig. S2G) display strong H3K27ac marks (SI Appendix,
Fig. S2I), characteristic of active regulatory elements (31), and are
mainly located outside promoter regions (31) (SI Appendix, Fig.
S2H) and thus correspond to active enhancers. We found that
Chd7 binds many H3K27ac+ Sox10/Olig2-active enhancers both in
OPCs and OLs (Fig. 1I). Unexpectedly, in OPCs Chd7 binding
was especially enriched in promoter regions defined by either
H3K4me3/H3K27ac active promoter marks or the Genomatix
portal (Fig. 1J and SI Appendix, Fig. S2 J and K), contrary to rare
Chd7 binding to promoters in other cell types, such as OLs, GNPs
(21), and ESCs (30). Taken together, our data suggest that
Chd7 binding to promoters is temporally restricted to the OPC
stage while Chd7 binds to enhancers both in OPCs and OLs.
Chd7 Regulates Genes Involved in OPC Proliferation, Differentiation,
and Survival. To investigate whether the expression of Chd7-
bound genes in OPCs was modified upon Chd7 LOF, we induced
Chd7-conditional deletion (Chd7iKO) in neonatal OPCs, using
PDGFRa-CreERT and Chd7Flox alleles (32, 33) (Fig. 2A). Neo-
natal tamoxifen administration allowed us to delete Chd7 in
∼90% of OPCs, as shown by Chd7 immunofluorescence and
qRT-PCR at P7 (Fig. 2 B and C and SI Appendix, Fig. S3A). We
then purified O4+ cells from Chd7iKO (PDGFRα-CreERT;
Chd7Flox/Flox) or control (Chd7Flox/Flox) (Fig. 2A) P7 cortices.
Because the proportion of OL stages (80% of OPCs and 20%
iOLs) was not altered by the loss of Chd7 (SI Appendix, Fig.
S2C), we could collect comparable oligodendroglial cell pop-
ulations from mutant and control brains.
The impact of Chd7 LOF on gene transcription was assessed
by genome-wide transcriptome analysis (RNA-seq) (Fig. 2A).
Surprisingly, despite Chd7 being described mostly as an activator
of transcription (17, 18, 21), many deregulated genes in Chd7iKO
OPCs (3,096 genes, fold-change > 1.2 and P < 0.05) were up-
regulated (67%, 2,070 genes) (Fig. 2D), while only 33% were
down-regulated (1,026 genes) (Fig. 2D). GO analysis indicated
that many up-regulated genes were associated with cell survival,
apoptosis, and cell proliferation (Fig. 2E and SI Appendix, Fig. S3
B–D). In contrast, genes associated with OL differentiation were
exclusively found among down-regulated genes (Fig. 2F and SI
Appendix, Fig. S3 C and D). Almost all genes Chd7-bound and
deregulated in Chd7iKO OPCs had a dynamic expression pattern
during OPC differentiation (SI Appendix, Fig. S3E). On the one
hand, one-third (31%) of up-regulated genes were bound by
Chd7, including cell-cycle regulators (e.g., Ccnd1, Cdk4 and
Cdk6) and regulators of cell survival/apoptosis (e.g., p53/Trp53,
Bax, Apaf1) (Fig. 2G). On the other hand, a majority of down-
regulated genes (59%) were bound by Chd7, including genes
involved in OPC differentiation (such as Sox10, Nkx2.2, Gpr17,
and Sirt2) (Fig. 2G). Therefore, Chd7 regulates OPC gene
Fig. 2. Chd7-regulated genes involved in OPCs proliferation, differentiation,
and survival. (A) Diagram representing tamoxifen (Tam) administration to
control (Ctrl) and Chd7iKO (iKO) mice at P1 and P4 followed by MACS-sorting
of O4+ cells at P7. Cells are then used for either RNA-seq or ATAC-seq. (B)
Immunostaining of P7 brain sections showing that all PDGFRα+ OPCs express
Chd7 in the CC of Ctrl mice, while only a few OPCs maintain Chd7 expression
in iKO mice. Star shows a Chd7-expressing OPC in iKO. (Scale bars, 10 μm.) (C)
Quantification of Chd7+ OPCs as a percentage of total PDGFRα+ cells in the CC
and cortex (Ctx) of P7 Ctrl and iKO mice. Data are presented as mean ± SEM
(n = 5). Exact P values can be found in Dataset S2. ***P < 0.001. (D) Pie chart
showing the relative percentage and number of genes that were significantly
up-regulated or down-regulated in P7 iKO O4+ cells compared with Ctrl (fold-
change > 1.2; P < 0.05). (E) GO analysis of the up-regulated (red) and down-
regulated (blue) genes in Chd7iKO cells compared with Ctrl. Numbers indicate
the number of genes of each category. (F) Heatmap representing the ex-
pression of 100 most different genes in Ctrl and iKO O4+ cells (n = 7 Ctrl and 5
iKO). (G) Venn diagram depicting the overlap of Chd7-binding genes in OPCs
with down-regulated (blue) or up-regulated (red) genes in iKO cells with ex-
amples of Chd7-bound genes involved in OL differentiation (blue), cell death
(orange), and cell cycle (red).
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transcription by both repressing apoptosis/proliferation genes
and activating differentiation genes.
Chd7 and Chd8 Bind to the Same Regulatory Regions of OPC
Differentiation, Proliferation, and Survival Genes. Combined
Chd7 chromatin-binding and transcriptomics analysis of Chd7
mutant OPCs indicate that, despite Chd7 binding to many genes
involved in different OPC functions, only a fraction of these genes
are deregulated upon Chd7 deletion (Fig. 2G). We therefore
asked if Chd8 cooperates with Chd7 and compensates for Chd7
LOF in the regulation of Chd7-bound genes. We thus investigated
Chd8 protein expression in the postnatal brain. Indeed, Chd7 and
Chd8 proteins showed similar expression patterns in postnatal
brain oligodendroglia; Chd8 protein was detected in PDGFRα+
OPCs (Fig. 3 A and C, arrowheads) and found at higher levels in
differentiating OLs (CC1high cells) (Fig. 3 A and C, arrows), and
its levels decreased in mature MOG+ OLs (Fig. 3 B and C, ar-
rows), in agreement to Chd8 transcript pattern in postnatal brain
cells shown by RNA-seq databases (34, 35). Furthermore, upon
LPC-induced focal demyelination of the adult corpus callosum
(CC), Chd8 was detected at high levels in PDGFRα+ OPCs and
iOLs (CC1+/Olig1+ cells) in/around lesions during remyelination
(SI Appendix, Fig. S4 A–E), similar to Chd7 expression (SI Ap-
pendix, Fig. S1 J and K). Chd8 protein may thus compensate for
Chd7 LOF in differentiating OPCs/iOLs.
To investigate whether Chd7 and Chd8 regulate common OPC
genetic programs, a genome-wide Chd8 chromatin-binding profile
was established from in vivo purified OPCs and then compared
with Chd7-binding sites. Chd8 and Chd7 share many sites
(6,418 regions) (Fig. 3D), representing 55% of Chd7-bound re-
gions. A majority (57.6%) of Chd8-binding sites were found in
promoter regions (Fig. 3E), consistent with reports of other cell
types (22, 36). In addition, Chd8, like Chd7, also bound a large
number of OPC active enhancers (Fig. 3F). Interestingly, the
majority of Chd7-bound genes were also bound by Chd8 (86%,
5,184 genes), including genes associated with cell differentiation,
proliferation, and survival (Fig. 3G). Furthermore, the genes
encoding well-known regulators of oligodendroglial development
(Ascl1, Nkx2.2, Olig1, Olig2, Sox10), oligodendroglial markers
(Pdgfra, Cspg4, Gpr17, Apc, Itpr2, Mbp), R checkpoint regulators
(Ccnd1, Cdk4, Cdk6), and apoptotic/survival genes (p53, Bax,
Apaf1) were all bound by both Chd7 and Chd8 (Fig. 3G and I). Of
Fig. 3. Chd8 binds together with Chd7 to OPC differentiation, proliferation, and survival genes. (A) Chd8 immunolabeling of P14 brain sections showing
Chd8 expression in all maturing OLs (CC1high-expressing cells, arrows) of the CC, as well as in neurons of the cortex (Ctx). (A1) Detail of the Inset in A showing
that, beside the high Chd8 expression in maturing OLs (white arrows) and neurons (gray arrows), a low level of Chd8 expression is detected in few OPCs
(PDGFRα+ cells, white arrowheads) but is hardly detectable in astrocytes (CC1low-expressing cells, gray arrowheads). (Scale bar, 20 μm.) (B) Immunofluorescence at
P21 showing young mature MOG+ OLs still expressing Chd8 (white arrows). (B1) Detail of the Inset shown in B; gray arrows correspond to Chd8+ neurons. (Scale
bar, 20 μm.) (C) Summary representation of Chd8 and Chd7 expression at different stages of the OL cell lineage, as identified by PDGFRα, CC1, and MOG ex-
pression. (D) Venn diagrams depicting the overlap of Chd7-, Chd8-, and Brg1-binding sites in OPCs. (E and F) Graph showing the number of correlations of Chd7
(blue), Chd8 (red), and Chd7-Chd8 (green) peaks in OPCs compared with the position in promoter regions (E) or enhancer regions (F). (G) Overlap of Chd7- and
Chd8-bound genes in OPCs with examples of genes involved in OL cell differentiation (blue), cell death (orange), and cell cycle (red). (H) Overlap between ASD-
risk genes and Chd7- and Chd8-bound genes in OPCs. (I) Representative ChIP-seq tracks for Chd8 and control IgG together with Olig2, Sox10, Chd7, and active
epigenetic marks (H3K27ac and H3K4me3) in Olig2, Olig1, Sox10, Mog, and Cdk1 gene regions in OPCs.
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note, Chd7 and Chd8 share very few binding sites with Brg1 (Fig.
3D), another chromatin remodeler that cooperates with Olig2 to
control OL differentiation (15), suggesting that Chd7/Chd8 and
Brg1 may regulate distinct OPC differentiation processes. Given that
we integrated ChIP-seq datasets obtained from rat and mouse, we
asked whether binding is conserved between species. To address this
question, we compared the Chd8-binding profile between our in vivo
mouse-purified O4+ cells with rat OPC primary cultures (37) and
observed a large overlap (87%) (SI Appendix, Fig. S5B) of bound
genes between species, comparable to the reported overlap of Chd8
ChIP-seq replicates from the same sample (36, 38). Furthermore,
global alignment of Chd7-, Chd8-, Olig2-, and Sox10-binding peaks to
active regulatory regions found in oligodendroglial cells, but not in
other neural cells (Fig. 3I and SI Appendix, Figs. S5–S8), strongly
support cell-type–specific binding conservation to regulatory elements
in orthologous chromosomic regions, consistent with conservation in
TF-to-TF connections and regulatory networks found in mammals by
the ENCODE project (39). Taken together, our findings show that
Chd7 and Chd8 chromatin remodelers, acting together or functionally
compensating for each other, regulate the genetic networks control-
ling OPC proliferation, survival, and differentiation.
Finally, we assessed whether Chd7 and Chd8 binding to OPC
genes was enriched among 201 ASD risk genes described pre-
viously (40, 41). A large number of them were Chd7/Chd8-bound
genes in OPCs (90 of 201 and 136 of 201, respectively) (Fig. 3H and
Dataset S1), but only Chd7 was found to be significantly enriched
over its genome-wide binding to protein-coding genes (P < 0.0034,
hypergeometric test), suggesting that OPCs may contribute to brain
developmental defects in ASD patients displaying mutations in
either CHD8, CHD7, or their targets among ASD-risk genes.
Chd7 LOF Reduces Brain OPC Pool Without Impacting OPC
Proliferation. To determine the consequences of Chd7 LOF in
OPC population, we quantified PDGFRα+ OPCs in P7 brains
and found that Chd7iKO brains display less numerous OPCs in
the CC and cortex, compared with controls (∼30% and ∼60%,
respectively) (Fig. 4 A and B). Chd7 deletion thus affects either
OPC proliferation or survival. To assess the possible impact of
Chd7 deletion on OPC proliferation, we examined proliferation-
associated genes in our OPC RNA-seq datasets and found an up-
regulation of key regulators of both cell-cycle checkpoints
(Ccnd1, Cdk6, Ccne1, Ccna1, Cdk2, Ccnb1, Cdk1) and pro-
liferation markers (Mki67, Mcm2) (Fig. 4C). Therefore, we
assessed the proliferative status of Chd7iKO OPCs in P7 brains.
Surprisingly, the number of Mcm2+ or Ki67
+ proliferating OPCs
in the CC and cortex was similar between Chd7iKO and controls
(Fig. 4 D and E and SI Appendix, Fig. S9 A–E). We then
addressed possible changes in cell-cycle length measuring the
proportion of OPCs in S-phase (labeled by short pulse of BrdU)
among cycling OPCs (MCM+/PDGFRα+ cells) and found no
changes in cell-cycle length between Chd7iKO and controls at P7
(SI Appendix, Fig. S9 G and H).
These results led us to hypothesize that the up-regulation of
cell-cycle genes may result from a selective reduction of non-
proliferating OPCs. The number of cycling and noncycling OPCs
was counted in Chd7iKO and control brains, showing a reduction
of nonproliferative OPCs (Mcm2−/PDGFRα+ cells) (Fig. 4 D
and E and SI Appendix, Fig. S9B), leading to an increased
MCM2+ fraction of OPCs (Fig. 4F and SI Appendix, Fig. S9C) in
Chd7iKO brains. Similar results were obtained upon Chd7 de-
letion in OPCs at a later time point (SI Appendix, Fig. S9 I and J).
Therefore, Chd7-deficient brain OPCs are not impacted in their
proliferation or cell-cycle length. In contrast, nonproliferative
Chd7-deficient OPCs are reduced in numbers, suggesting that
Chd7 may regulate OPC survival.
Chd7 Promotes OPC Survival by Chromatin-Closing and Transcription
Repression of p53.We next investigated whether OPCs underwent
abnormal apoptosis in P7 Chd7iKO brains. Despite being actively
removed by microglia (SI Appendix, Fig. S9K), apoptotic OPCs
labeled with antiactivated Caspase3-recognizing antibodies
(Casp3+/PDGFRα+ cells) were observed in Chd7iKO brains,
while they were rare in controls (Fig. 5 A and B). Furthermore,
the apoptosis GO category was highly enriched among the up-
regulated transcripts of purified OPCs from Chd7iKO brains
compared with controls (RNA-seq) (Figs. 2E and 5C). Notably,
transformation-related protein 53 (Trp53 also named p53), a
main regulator of apoptosis, and recently linked to Chd7-
mediated defects in CHARGE syndrome (42), was among the
up-regulated transcripts (Fig. 5C) and confirmed by qRT-PCR
(SI Appendix, Fig. S10A). Several p53 target genes involved in
apoptosis (e.g., Bax, Apaf1) were also up-regulated, but not those
involved in cell-cycle arrest (expecting p21) or DNA repair (Fig.
5C). We therefore assessed for p53 protein up-regulation in
P7 cerebral OPCs and found p53+ OPCs (15% of CC OPCs and
40% of cortical OPCs) in Chd7iKO brains but not in controls
(Fig. 5 D–F). Interestingly, 90% of Chd7iKO OPCs expressing
p53 were postmitotic (Mcm2−/PDGFRα+ cells) (Fig. 5G), con-
firming that loss of Chd7 results in specific apoptosis of non-
cycling OPCs likely mediated by p53 up-regulation (Fig. 5M).
To obtain more insight into Chd7 regulation of Chd7-bound
genes, we compared the chromatin accessibility of these genes
between Chd7iKO and control OPCs. Therefore, we generated a
genome-wide chromatin accessibility profiling by Tn5 transposase-
accessible chromatin with high-throughput sequencing (ATAC-
seq) combined with sequencing (43), from purified O4+ cells
from either Chd7iKO or control cortices (Fig. 2A). We obtained a
high genome-wide correlation between transcript expression and
chromatin accessibility in the transcription start sites, indicating
efficient open chromatin mapping (SI Appendix, Fig. S10B). In-
terestingly, the promoter elements bound by Chd7 and Chd8 in
the p53/Trp53 locus showed larger chromatin accessibility in
Chd7iKO OPCs compared with controls (Fig. 5H), suggesting that
Fig. 4. Chd7 LOF in OPCs does not affect cell proliferation. (A) Immunolab-
eling of PDGFRα+ cells in the CC and cortex (Ctx) of P7 Control (Ctrl) and
Chd7iKO (iKO) mice. (Scale bars, 10 μm.) (B) Quantification of PDGFRα+ cells
(nb/mm2) in the CC and Ctx of P7 Ctrl and iKO mice. Data are presented as
mean ± SEM (n = 5). (C) Barplot representing the log fold-change (LogFC) of
genes involved in cell cycle and proliferation between iKO and Ctrl mice.
Dashed gray line represent FC = 1.2 (n = 7). (D) Immunostaining of MCM2 and
PDGFRα in the CC from P7 Ctrl and iKO mice. (Scale bars, 10 μm.) (E) Quan-
tification of the density of MCM2+ and MCM2− PDGFRα+-OPCs (nb/mm2) in
the CC of P7 Ctrl and iKOmice. Data are presented as mean ± SEM (n = 3). (F)
Quantification of MCM2+ cells as a percentage of total PDGFRα+ cells in the
CC of P7 Ctrl and iKOmice. Data are presented as mean ± SEM (n = 3). Exact P
values can be found in Dataset S2. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Chd7 normally represses p53/Trp53 transcription by binding and
inducing chromatin closing at these regulatory elements.
To demonstrate that p53 up-regulation was responsible for
Chd7iKO OPCs apoptosis, we used Pifithin-α (PFT) (Fig. 5I), a
p53 inhibitor that impedes p53 activation (44). Interestingly,
treatment with PFT reduced the number of p53+ OPCs (Fig. 5J)
and rescued the normal density of OPCs in Chd7iKO CC (Fig. 5 I
and K), indicating that Chd7 promotes OPC survival by inhibit-
ing p53-mediated apoptosis. Notably, rescuing noncycling OPCs
permitted to recover a similar proportion of MCM2+ OPCs
between control and Chd7iKO brains (Fig. 5L), confirming that
Chd7-deletion does not have an impact on brain OPC pro-
liferation. Together, these results indicate that Chd7 contributes
to the survival of postmitotic OPCs by inhibiting p53/Trp53
through chromatin closing at its promoter elements (Fig. 5M).
Chd7 Is Required to Induce OPC Differentiation but Not OL Stage
Progression, by Chromatin-Opening, and Gene Activation of Sox10,
Nkx2.2, and Gpr17. We then assessed for the Chd7 role in OPC
differentiation that was not been specifically addressed in our
previously study (28). In depth analysis of down-regulated tran-
scripts in Chd7iKO oligodendroglia showed reduced expression
of key regulators of OPC differentiation, such as Sox10, Gpr17,
Nkx2.2, and Tcf7l2 (Fig. 6A). Chd7 LOF also impacted the ex-
pression of some regulators of OL maturation (Sirt2, Myrf,
Zfp488) and in myelin protein genes (Cnp, Omg) (Fig. 6A).
These results were confirmed by qPCR analysis (SI Appendix,
Fig. S10A). Therefore, we quantified the different OL cell types
in the CC of Chd7iKOmice at postnatal stage P7, a peak time for
cortical OPC differentiation. P7 Chd7iKO mice showed a strong
decrease (∼40%) of Nkx2.2+ iOLs compared with control brains
(Fig. 6 B and C), indicating that Chd7 deletion in OPCs impairs
normal OPC differentiation. The OPC/iOL ratio was, however,
not modified in Chd7iKO brains, due to a similar reduction in
OPC and iOL populations (SI Appendix, Fig. S10 C and D). The
number of Nkx2.2+, Itpr2+ (35), and APC+ (45) cells, which we
show by immunofluorescence, mark successive stages of OL cell
lineage according to their transcript expression pattern (SI Ap-
pendix, Fig. S10 E–H), were similarly decreased (Fig. 6 B and C),
indicating that Chd7 loss do not alter OL stage progression once
OPC differentiation is started. In agreement with this in-
terpretation, we found a similar CC1/Olig1 immunofluorescence,
which distinguishes three different stages of OL differentiation
(13), between Chd7iKO mice and controls (SI Appendix, Fig.
S11). Taken together, these data indicate that Chd7 deletion
impairs OPC capacity to start differentiation but not the normal
progression once differentiation has started (Fig. 6F).
To assess whether OPC apoptosis was sufficient to account for
the reduction of differentiating OLs in Chd7iKO brains, or if
Chd7 functions in survival and differentiation could be sepa-
rated, we rescued OPC survival and numbers by PFT treatment
(Fig. 5 I and K). Remarkably, the number of iOLs (Nkx2.2+ cells)
in the CC was the same in PFT-treated and untreated Chd7iKO
mice (Fig. 6 D and E). Therefore, the rescue of OPC survival
is not sufficient to recover normal differentiation of Chd7iKO
Fig. 5. Chd7 promotes OPC survival through p53 down-regulation. (A)
Immunostaining of Casp3 and PDGFRα in the CC of P7 iKO mice. (Scale bar,
10 μm.) (B) Quantification of Casp3+ OPCs as a percentage of OPCs in P7 Ctrl
and iKO mice. Data are presented as mean ± SEM (n = 3 Ctrl and 4 iKO). (C)
Barplot representing the LogFC of Trp53 and p53 target-genes involved in
apoptosis pathway (red), cell-cycle arrest (orange), or DNA repair (yellow)
between iKO and Ctrl mice. Dashed gray line represents FC = 1.2 (n = 7 Ctrl
and 5 iKO). (D) Immunostaining of p53 and PDGFRα in the CC from P7
Ctrl and iKO mice. (Scale bars, 10 μm.) (E and F) Quantification of p53+
OPCs (nb/mm2, E) or as a percentage of OPCs (F) in the CC and Ctx of P7 Ctrl
and iKO mice. Data are presented as mean ± SEM (n = 3 Ctrl and 4 iKO). (G)
Quantification of MCM2+ and MCM2− cells as a percentage of total p53+ cells
in the CC of iKO P7 mice. Data are presented as mean ± SEM (n = 3 Ctrl and 4
iKO). (H) Representative tracks for Trp53 locus integrating: (i) ChIP-seq data
for Olig2 and Sox10, Chd7, and Chd8 in OPCs and; (ii) ATAC data from Ctrl
and iKO P7 OPCs. (I, Left) Diagram representing tamoxifen (Tam) adminis-
tration at P1 and P4 and PFT injection at P3, P4, and P5 followed by tissue
collection at P7. (Right) Immunostaining of PDGFRα in the CC from P7 Ctrl,
iKO and iKO+PFT mice. (Scale bars, 10 μm.) (J) Quantification of p53+ cells as
a percentage of OPCs in the CC of P7 Ctrl, iKO, Ctrl+PFT, and iKO+PFT mice.
Data are presented as mean ± SEM (n = 3 Ctrl, 4 iKO, 3 Ctrl+PFT and 3 iKO+
PFT). (K) Quantification of PDGFRα+ cells (nb/mm2) in the CC of P7 Ctrl, iKO,
Ctrl+PFT and iKO+PFT mice. Data are presented as mean ± SEM (n= 5 Ctrl, 5
iKO, 3 Ctrl+PFT and 3 iKO+PFT). (L) Quantification of MCM2+ cells as a
percentage of OPCs in the CC of P7 Ctrl+PFT and iKO+PFT mice. Data are
presented as mean ± SEM (n = 3). (M) Scheme representing Chd7 function in
OPC survival. Proliferative OPCs (light blue), noncycling OPCs (blue) in Ctrl,
iKO, and iKO+PFT mice. Exact P values can be found in Dataset S2. *P < 0.05,
**P < 0.01, and ***P < 0.001.
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OPCs, indicating that Chd7 functions in OPC survival and dif-
ferentiation can be dissociated (Fig. 6F).
To address Chd7 remodeling function in the loci involved in
OPC differentiation, we compared their chromatin accessibility
in Chd7iKO OPCs and controls. Interestingly, OL differentiation
genes bound by Chd7, such as Olig2, Olig1, and Gpr17 (coding
for a G protein-coupled receptor involved in OL differentiation),
showed a decreased chromatin accessibility at regulatory regions
in Chd7 mutant OPCs compared with controls (Fig. 6G).
Therefore, our findings indicate that Chd7 promotes chromatin
opening of key factors involved in OPC differentiation.
OPC Differentiation Requires both Chd7 and Chd8 Remodelers. To
study whether Chd8 and Chd7 are required during OPC differen-
tiation, we transfected neural progenitors derived from the neo-
natal SVZ of Rosa26Rflox-stop-YFP or Chd7flox/+;Rosa26Rflox-stop-YFP
mice with lentivirus-expressing Cre-recombinase together with
either Chd8 shRNA or scramble shRNA (Fig. 7A). After 3 d in
differentiation conditions favoring oligodendroglial differentia-
tion (40% of cells) (SI Appendix, Fig. S12 A–C), Chd7 and
Chd8 levels were found to be successfully reduced in Chd8KD
(shChd8) and Chd7cKO/+ (Chd7flox/+) conditions compared with
control (ShScramble), but the number of OPCs was not altered
(SI Appendix, Fig. S12 D–H). At 6 d of differentiation, we found
many iOLs expressing strong levels of both CNP and Nkx2.2 (SI
Appendix, Fig. S12I). Interestingly, while all genotypes showed
comparable numbers of PDGFRα+ OPCs and cell densities (Fig.
7 B and F), the ratio iOL/OPCs (Nkx2.2+/PDGFRα+ cells) was
reduced by 36% in Chd8KD cells (Fig. 7 B and C), suggesting a
requirement of Chd8 in OPC differentiation. Furthermore, while
the loss of one Chd7 allele (Chd7cKO/+ cells) did not modify
their OPC differentiation, its combination with Chd8KD further
reduced iOL/OPC ratio (Fig. 7 B and C). These results thus
indicate that Chd7 and Chd8 genetically interact in the process
of OPC differentiation and suggest that Chd8 may partially
compensate the loss of Chd7 during OPC differentiation.
Chd7/Chd8 and Olig2/Sox10 Bind to Regulatory Elements of Active
Stage-Specific Genes in Oligodendroglia. Finally, we further in-
vestigated the mechanisms by which Chd7/Chd8 control gene
expression in a timely manner during the course of OL cell
lineage differentiation, integrating different datasets. An oligo-
dendroglia single-cell transcriptome database (35) was used to
classify genes according to their expression timing (Fig. 8A).
Focusing on oligodendroglial stage-specific gene expression, we
classified oligodendroglial-genes into three groups: (i) “OPC-
genes” expressed in OPCs and down-regulated upon differenti-
ation (e.g., Ascl1, Cspg4, Pdgfra); (ii) “iOL-genes” up-regulated
and maintained upon early OPC differentiation (COPs of ref. 35;
e.g., Nkx2.2, Gpr17, Itpr2); and (iii) “mOL-genes” up-regulated
only in maturing OLs (NFOLs and mOLs; e.g.,Mbp,Mog, Omg).
We then integrated the chromatin-binding profiles for key TFs
(Sox10 and Olig2), chromatin remodelers (Chd7 and Chd8), and
active histone marks (H3K4me3 and H3K27ac) (Fig. 8 and SI
Appendix, Fig. S13) (present study and refs. 15 and 28) to analyze
genes of each group (OPC-, iOL-, and mOL-genes’; n = 20) (SI
Appendix, Table S1). This integrative approach allowed us to
identify four regulatory states, which are recapitulated in Fig. 8H
and outlined as follows. State 1: Among not-yet-expressed genes,
such as the majority of mOL-genes in OPCs, only a few are
bound by Chd7, Chd8, and Sox10, while all are bound by Olig2 in
agreement with the pioneer factor function of Olig2 (15). State 2:
Among genes at their expression-onset (that start to be
expressed), such as iOL-genes in OPCs, all are bound by Chd8,
Chd7, and Olig2 (to less extent by Sox10) at enhancers but only a
few at their cognate promoters. State 3: Among robustly
expressed genes, such as most OPC-genes in OPCs and iOL- and
mOL-genes in OLs, all are bound by all factors (Chd7, Chd8,
Fig. 6. Chd7 promotes the expression of genes involved in OPC differenti-
ation and maturation. (A) Barplot of the LogFC of genes involved in OPC
differentiation, OL maturation, or coding for myelin proteins between
P7Chd7iKO (iKO) and Ctrl. The dashed gray line represents fold-change = 1.2
(n = 7 Ctrl and 5 iKO). (B) Immunostaining of Itpr2 and APC together with
Nkx2.2 and Olig1 in the CC from P7 control (Ctrl) and iKO (iKO) mice. (Scale
bars, 10 μm.) (C) Quantification of Nkx2.2+, Itpr2+, and APC+ cells (nb/mm2)
in the CC of P7 Ctrl and iKO mice. Data are presented as mean ± SEM (n = 4
Ctrl and 5 iKO). (D) Immunostaining of PDGFRα and Nkx2.2 in the CC from P7
Ctrl, iKO, and iKO+PFT mice. (Scale bars, 10 μm.) (E) Quantification of
Nkx2.2+ cells (nb/mm2) in the CC of P7 Ctrl, iKO, Ctrl+PFT and iKO+PFT mice.
Data are presented as mean ± SEM (n = 3 Ctrl, 5 iKO, 3 Ctrl+PFT and 3 iKO+
PFT). (F) Summary representation of OL cell lineage progression in P7 iKO
and iKO+PFT, mice. Circle size is proportional to the size of OL lineage cell-
type population, as quantified in the CC. Dotted lines: OL population size in
Ctrl. (G) Representative tracks for Olig1, Olig2, Gpr17, and Mbp locus in-
tegrating: (i) ChIP data for main oligodendroglial TFs (Olig2 and Sox10) and
chromatin remodeling factors (Chd7, Chd8) in OPCs and; (ii) ATAC data from
Ctrl and iKO P7 OPCs. Exact P values can be found in Dataset S2. *P < 0.05,
**P < 0.01, and ***P < 0.001.
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Olig2, and Sox10) both at enhancers and their cognate pro-
moters, suggesting that the presence of all these factors drive
active gene transcription, with Sox10 preferentially binding ac-
tive genes in OLs compared with OPCs. State 4: Among silenced
genes (not expressed anymore), such as OPC-genes in OLs, all
are still bound by Olig2 and Sox10, while a majority of them have
lost Chd7 and Chd8 binding, suggesting that gene silencing is
marked by, or results from, the lack of binding of chromatin
remodelers, and not of TFs.
We therefore propose a dynamic model of cooperation be-
tween Chd7/Chd8 remodelers and Olig2/Sox10 key oligoden-
drogenic TFs to select and timely tune the gene-expression
program at different OL lineage stages, in which the present of
chromatin remodelers is key for robust gene transcription (SI
Appendix, Fig. S14).
Discussion
Mounting evidence indicates that chromatin remodeling factors
play important roles in normal development and neurodeve-
lopmental diseases (46), with CHD7 haploinsuficiency being the
cause of CHARGE syndrome (47) and CHD8 being one of the
strongest ASD high-risk–associated genes (25). It is thus of rele-
vance for human health to unravel the mechanisms controlled by
Chd7/Chd8 chromatin remodelers and to understand how their
haploinsuficiency leads to developmental brain pathology involved
in these diseases. The present study addresses the mechanisms of
gene-expression control by Chd7/Chd8 in OPCs, by generating
and integrating genome-wide transcriptome, chromatin binding,
and chromatin accessibility profiles of purified OPCs, isolated
from control and OPC-specific Chd7-deficient mice. These expe-
riences led to the following conclusions (SI Appendix, Fig. S15).
First, Chd7 and Chd8 bind together to regulatory regions of genes
involved in OPC differentiation, proliferation, and survival, sug-
gesting that they regulate these different biological processes.
Second, Chd7 protects OPCs from cell death through chromatin
closing and direct transcriptional repression of the p53/Trp53
promoter. Third, Chd7 is partially required to induce OPC dif-
ferentiation through chromatin opening and transcriptional
activation of key regulators of this process, although being dis-
pensable for OL stage progression, consistent with Chd8 com-
pensatory function, as suggested by Chd7/Chd8 common chromatin-
binding profile and genetic synergy during OPC differentiation.
Finally, integration of genome-wide occupancy repertoires and
associated epigenetic signals from OL lineage cells suggests that
Chd7/Chd8 remodelers and Olig2/Sox10 TFs cooperate to acti-
vate oligodendroglia stage-specific genes.
Chd7 Promotes OPC Survival Through Direct p53/Trp53 Down-
Regulation. Our timely controlled Chd7 deletion in OPCs pro-
vided insights into Chd7 function in proliferation and survival that
were not directly addressed in our previous work using this time-
controlled Chd7 deletion (29). Interestingly, we found that Chd7
OPC-specific deletion leads a selective apoptosis of noncycling
OPCs and that the p53/Trp53 transcripts were up-regulated in
Chd7-deleted OPCs. Notably, Trp53 heterozygosity has been re-
cently shown to partially rescue the phenotypes of Chd7-null mouse
embryos, and p53 inappropriate activation leads to CHARGE
syndrome traits (42). Here, we provide evidence that in vivo,
Chd7 directly represses p53/Trp53 expression in OPCs by binding
and inducing chromatin closing at its promoter. These results are
consistent with recent in vitro evidence for Chd7 binding to the
p53/Trp53 promoter in neural crest cells (42). Using a p53 inhibitor
(PFT), we were able to prevent p53/Trp53 induction and cell death,
thus restoring the pool of OPCs. It is worth noting that rescuing
normal OPC numbers was not sufficient to restore normal OPC
differentiation, indicating that Chd7 function in OPC survival can
be dissociated from its role in promoting OPC differentiation.
The above results point out PFT as a potential treatment to
reduce p53 inappropriate expression in CHARGE patients.
However, our PFT treatment rescued normal OPC numbers but
not normal OPC differentiation, suggesting that targeting gene-
networks promoting cell-differentiation may also be required to
restore CHD7 function in CHARGE patients. The Chd7 direct
repression of p53/Trp53 in OPCs also has a potential interest in MS
becauseMS brain tissues up-regulate p53 expression (48), suggesting
that a transient, and if possible brain-restricted, administration of
Fig. 7. OPC differentiation requires both Chd7 and Chd8 remodelers. (A)
Diagram representing transduction protocol used on neural stem cells (NSCs)
with a lentivirus-expressing Cre and a scramble shRNA or a shRNA against
Chd8 and followed by fixation after 6 d of differentiation. (B) Immunostaining
of Nkx2.2 and PDGFRα together with GFP in Ctrl (ROSA26Rstop-floxed-YFP +
scramble), Chd8KD (ROSA26Rstop-floxed-YFP +Chd8 shRNA), Chd7cKO/+
(Chd7Flox/+;ROSA26Rstop-floxed-YFP +scramble), or Chd7cKO/+;Chd8KD
(Chd7Flox/+;ROSA26Rstop-floxed-YFP +Chd8 shRNA) conditions. White arrow-
heads represent PDGFRα+-GFP+ OPCs and gray arrowheads represent
Nkx2.2+-GFP+ iOLs. (Scale bars, 20 μm.) (C and D) Ratio between Nkx2.2+-
GFP+ iOLs and PDGFRα+-GFP+ OPCs (C) and between Nkx2.2+-GFP− iOLs and
PDGFRα+-GFP− OPCs (D) in Ctrl, Chd8KD, Chd7cKO/+, and Chd7cKO/+;
Chd8KD conditions. Data are presented as mean ± SEM (n = 4). (E) Quan-
tification of PDGFRα+-GFP+ cells as a percentage of total GFP+ cells in Ctrl,
Chd8KD, Chd7cKO/+, and Chd7cKO/+;Chd8KD conditions. Data are pre-
sented as mean ± SEM (n = 3). (F) Quantification of cells (nb/mm2) in Ctrl,
Chd8KD, Chd7cKO/+, and Chd7cKO/+;Chd8KD conditions. Data are pre-
sented as mean ± SEM (n = 3). Exact P values can be found in Dataset S2. *P <
0.05, **P < 0.01, and ***P < 0.001.
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PFT to avoid possible proinflammatory effects (49), may help in the
treatment of MS patients.
Diverse Chd7 Activities Regulate Different OPC Functions.Our ChIP-
seq analyses on brain-purified OPCs allowed us to produce an
in vivo genome-wide chromatin-binding profiling available for
Chd7 and Chd8. In addition, the comparative transcriptome
(RNA-seq) and chromatin accessibility (ATAC-seq) analyses
performed between control and Chd7-deficient OPCs led us to
demonstrate that Chd7 directly binds and opens chromatin at
the enhancer and promoter regions of key regulators of OPC dif-
ferentiation, such as Sox10, Nkx2.2, and Gpr17. The role of Chd7 in
OPCs, as a chromatin-opening factor and activator of differentiation,
is consistent with Chd7 function in cerebellar granule progeni-
tors (21). Remarkably, Chd7-binding properties differ between
cell-types, as Chd7 binds to a completely different set of genes in
OPCs and granule neuron progenitors and Chd7 also acts as a
transcriptional repressor (closing chromatin) of many target
genes in OPCs (e.g., p53/Tpr53). These results raise important
questions that remain to be elucidated: first, whether the
cell-type–specific recruitment to regulatory elements of CHD
remodelers depends on particular histone modifications and on
the presence of cell-type–specific TFs; and second, what cofac-
tors determine their chromatin-opening versus -closing activity.
Mechanisms of Time-Controlled Gene Expression During OPC
Differentiation. We showed that in OL lineage cells, the binding
of Chd7/8 to OL-lineage TF genes varies upon their lineage stage.
This partial requirement of Chd7 during differentiation/matura-
tion of Chd7-deficient OPCs result at least in part from a func-
tional compensation provided by Chd8 which, like Chd7, binds to
the majority of OL differentiation genes in OPCs. Together with
our previous report on Chd7 expression during OL differentiation
and myelination (28), and our complementary study on Chd8 LOF
in OL lineage cells (37), the present results underscore CHD
chromatin remodelers as key regulators of the progression along
the differentiation/maturation pathway in OL lineage cells.
To further investigate the mechanisms regulating transcription
during OL differentiation, herein we integrated oligodendroglia-
specific chromatin profiling of chromatin remodelers (Chd7 and
Chd8), key TFs (Sox10 and Olig2), and epigenetic histone marks
(15, 28, 50). This integrative method highlighted a timely con-
trolled binding of Chd7 and Chd8 to stage-specific genes in OPCs
and OLs (Fig. 7). This finding leads us to propose a dynamic
transcription regulatory model (SI Appendix, Fig. S14), including
the following steps: (i) Olig2 pioneer TF (15, 51) binding to
chromatin-enhancer elements; (ii) Olig2 binding-mediated re-
cruitment of Chd7 and Chd8 on chromatin-enhancer elements;
(iii) Chd7- and Chd8-induced chromatin opening, likely by sliding
nucleosomes, results in Sox10 binding; (iv) additional clustering of
other regulators together with DNA bending activity of the Sox10
HMG domain, allowing the mediator complex to form a stable
promoter–enhancer loop; and (v) eventually, induction of robust
transcription of OL differentiation genes. This timing of events
could explain the crucial importance of Olig2 and Sox10 in acti-
vating OL lineage genes (12, 15), but also the partial compensa-
tion of Chd7 by Chd8 in OPC differentiation, cell survival, and
likely proliferation. Remarkably, we found that in OLs, most of
OPC-specific genes are still bound by Olig2 and Sox10 but not by
Chd7/Chd8 remodelers (Fig. 7). This could imply that the loss of
Chd7 and Chd8 binding, together with the recruitment of some
repressors (e.g., Nkx2.2) (14), is required for down-regulation of
OPC genes and subsequent OL differentiation.
Materials and Methods
Mice. Mice homozygous for Chd7 floxed alleles (Chd7Flox/Flox) (33) were
crossed with PDGFRα-CreERT (32) mice to generate the OPC-specific Chd7iKO
(iKO) mice. Animals of either sex were used in the study and PDGFRα-CreERT
Fig. 8. Chd7/Chd8 and Olig2/Sox10 bind to regulatory elements of active stage-specific genes in oligodendroglia. (A) Diagram representing a set of genes with
timely controlled expression (data from ref. 35) divided in three groups: OPC genes (Ascl1 and Pdgfrα), iOL genes (Nkx2.2 and Gpr17), and mOL genes (Mbp and
Omg). (B–G) Schematic representation from Genomatix genome browser of Ascl1 (B), Pdgfrα (C), Gpr17 (D), Nkx2.2 (E),Mbp (F), andOmg (G) locus integrating ChIP-
seq data for main oligodendroglial TFs (Olig2 and Sox10), chromatin remodeling factors (Chd7, Chd8), and active epigenetic marks (H3K27ac and H3K4me3) in OPCs
and OLs. (H) Synthesis representation of the dynamic cooperation between TFs (Sox10, Olig2) and chromatin remodelers (Chd7, Chd8) for the timely regulation of
OPC- and OL-gene expression with genes not yet expressed (1), genes starting to express (2), expressed genes (3), and genes not expressed anymore (4).
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negative littermates were used as controls (Ctrl). All animal studies were
conducted following protocols approved by Ethic Committee #5, Charles
Darwin and French regulatory authorities (#03860.07).
Tamoxifen Administration. For conditional Chd7 removal experiments, ta-
moxifen (T5648; Sigma) was dissolved in corn oil (C-8267; Sigma) and injected
subcutaneously at 20-mg/mL concentration at postnatal stages P1 (40 μL) and
P4 (30 μL) in Ctrl and Chd7iKO animals. Brains were then collected at P7.
PFT Administration. PFT (P4359; Sigma) was dissolved in DMSO (less than 10%
final) and NaCl and injected subcutaneously at 0.8-mg/mL concentration at
postnatal stages P3, P4, and P5 (5 μL per day). Brains were collected at P7.
OPC MACSorting. Dissociation of cortex and CC from Ctrl, Chd7iKO, or wild-
type P7 mice was done using neural tissue dissociation kit (P) (130–093-231;
Miltenyi Biotec) and dissociator (130-096-427). Magnetic sorting was done
using anti-O4–coupled-beads (130-094-543) and the MultiMACS Cell24 Sep-
arator Plus (130-098-637). O4+-cells were collected in PBS before being
process to RNA-seq, ATAC-seq or ChIP-seq.
ChIP-Seq, RNA-Seq, ATAC-Seq, and Data Analysis. A detailed description of the
methods used can be found in SI Appendix.
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